Article Dans Une Revue Advances in Therapy Année : 2024

Effect of Cariprazine on Anhedonia in Patients with Bipolar I Depression: Post Hoc Analysis of Three Randomized Placebo-Controlled Clinical Trials

Résumé

Introduction: Anhedonic symptoms in bipolar I (BP-I) depression are associated with decreased quality of life and impaired functioning. We evaluated the effects of cariprazine in patients with BP-I depression with lower or higher levels of anhedonia at baseline. Methods: Data were pooled from three clinical trials (NCT01396447, NCT02670538, NCT02670551) analyzing the effects of cariprazine 1.5 and 3 mg/day in adults with BP-I depression. During post hoc analysis, patients were stratified by baseline median Montgomery-Åsberg Depression Rating Scale (MADRS) anhedonia factor score into a lower (score < median) or higher (score ≥ median) anhedonia subgroup.

Outcomes included change from baseline to week 6 in MADRS total and anhedonia factor score, with the latter also evaluated after adjusting for other depressive symptoms. Betweengroup differences in change from baseline to week 6 were compared using least-squares mean differences (LSMD) analyzed via a mixed-effect model for repeated measures. Results: Median baseline anhedonia factor score was 19, defining the lower (placebo = 211; cariprazine 1.5 mg/day = 200, 3 mg/day = 212) and higher (placebo = 249; cariprazine 1.5 mg/ day = 261, 3 mg/day = 250) anhedonia subgroups. In the lower subgroup, cariprazine 1.5 mg/day but not 3 mg/day was superior to placebo in reducing MADRS total (LSMD [95% CI] 1.5 mg/ day = -2.61 [-4.28, -0.93], P = .0024) and anhedonia factor scores (-1.70 [-2.77, -0.62], P = .0021) at week 6. In the higher subgroup, both cariprazine doses were associated with significantly greater reductions than placebo in MADRS total (1.5 mg/day = -3.01 [-4.84, -1.19], P = .0012; 3 mg/day = -3.26 [-5.12, -1.40], P = .0006) and anhedonia factor scores (1.5 mg/ day = -1.97 [-3.13, -0.81], P = .0009; 3 mg/ day = -2.07 [-3.26, -0.89], P = .0006). Anti-anhedonic effects were preserved after adjusting for P r i o r P r e s e n t a t i o n E u r o p e a n C o l l e g e o f Neuropsychopharmacology, October 7-10, 2023, Barcelona, Spain (poster presentation).

Fichier principal
Vignette du fichier
Effect of Cariprazine on Anhedonia in Patients with Bipolar I Depression= Post Hoc Analysis of Three Randomized Placebo-Controlled Clinical Trials.pdf (863) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-04906705 , version 1 (22-01-2025)

Identifiants

Citer

Roger S Mcintyre, Pierre-Michel Llorca, Lauren C Aronin, Jun Yu, Huy-Binh Nguyen. Effect of Cariprazine on Anhedonia in Patients with Bipolar I Depression: Post Hoc Analysis of Three Randomized Placebo-Controlled Clinical Trials. Advances in Therapy, 2024, 42, pp.246-260. ⟨10.1007/s12325-024-03009-2⟩. ⟨hal-04906705⟩
0 Consultations
0 Téléchargements

Altmetric

Partager

More